Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies, has announced the publication of preclinical research supporting its engineered suppressor tRNA platform for Duchenne muscular dystrophy (DMD). The study, conducted by scientists at Tevard Biosciences, Johns Hopkins University, MIT, and the Whitehead Institute for Biomedical Research, appears in Science Advances under the title “Engineering suppressor tRNAs for effective treatment of Duchenne Muscular Dystrophy.” The paper is available at https://doi.org/10.1126/sciadv.aeg3466.
DMD is a severe genetic disorder caused by mutations in the dystrophin gene, many of which are nonsense mutations that prematurely halt protein production. The research describes an engineered suppressor tRNA gene therapy designed to overcome these mutations and restore the production of full-length dystrophin, a critical protein for muscle strength and stability. In a preclinical DMD model, the therapy restored physiological levels of full-length dystrophin, improved muscle strength and motor coordination, and was well tolerated.
A key finding is the exquisite selectivity of the engineered suppressor tRNAs. They targeted disease-causing nonsense mutations while leaving normal stop codons intact, a crucial safety feature that reduces the risk of unintended protein readthrough. This selectivity addresses a major challenge in developing treatments for nonsense mutation-driven diseases.
By targeting nonsense mutations as a class, the platform has potential beyond DMD and other muscular dystrophies. Tevard Biosciences is advancing a pipeline of programs spanning Duchenne muscular dystrophy, genetic cardiomyopathies, and neurological disorders, including epilepsies. The company’s proprietary suppressor tRNA platform is designed to restore endogenous, full-length protein expression for diseases caused by premature termination codons.
The implications of this announcement are significant. DMD currently lacks a cure, and existing therapies offer limited benefit. A therapy that restores full-length dystrophin could potentially modify the disease course rather than just manage symptoms. The positive preclinical results support further development and eventual clinical testing. If successful in humans, this approach could become a foundational treatment for DMD and other genetic diseases caused by nonsense mutations.
For more information about Tevard Biosciences, visit Tevard.com and follow the company on LinkedIn.
